These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26883709)

  • 1. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.
    Friedman ND; Athan E; Walton AL; O'Brien DP
    Antimicrob Agents Chemother; 2016 May; 60(5):2692-5. PubMed ID: 26883709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort.
    Friedman ND; Athan E; Hughes AJ; Khajehnoori M; McDonald A; Callan P; Rahdon R; O'Brien DP
    PLoS Negl Trop Dis; 2013; 7(7):e2315. PubMed ID: 23875050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
    O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
    PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients?
    Cowan R; Athan E; Friedman ND; Hughes AJ; McDonald A; Callan P; Fyfe J; O'Brien DP
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003503. PubMed ID: 25658304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.
    Klis S; Kingma RA; Tuah W; van der Werf TS; Stienstra Y
    Trop Med Int Health; 2016 Sep; 21(9):1191-6. PubMed ID: 27456068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
    Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
    Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wound healing: Natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease.
    O'Brien DP; Friedman ND; McDonald A; Callan P; Hughes A; Walton A; Athan E
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006357. PubMed ID: 29554101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patients.
    O'Brien DP; Friedman D; Hughes A; Walton A; Athan E
    Intern Med J; 2017 Sep; 47(9):1011-1019. PubMed ID: 28585259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    Tanywe A; Fernandez RS
    JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer.
    O'Brien DP; Friedman ND; Walton A; Hughes A; Athan E
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update.
    O'Brien DP; Jenkin G; Buntine J; Steffen CM; McDonald A; Horne S; Friedman ND; Athan E; Hughes A; Callan PP; Johnson PD
    Med J Aust; 2014 Mar; 200(5):267-70. PubMed ID: 24641151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
    Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).
    Kibadi K; Boelaert M; Fraga AG; Kayinua M; Longatto-Filho A; Minuku JB; Mputu-Yamba JB; Muyembe-Tamfum JJ; Pedrosa J; Roux JJ; Meyers WM; Portaels F
    PLoS Negl Trop Dis; 2010 Jul; 4(7):e736. PubMed ID: 20625556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin.
    Chauty A; Ardant MF; Marsollier L; Pluschke G; Landier J; Adeye A; Goundoté A; Cottin J; Ladikpo T; Ruf T; Ji B
    Clin Infect Dis; 2011 Jan; 52(1):94-6. PubMed ID: 21148526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan.
    Sugawara M; Ishii N; Nakanaga K; Suzuki K; Umebayashi Y; Makigami K; Aihara M
    J Dermatol; 2015 Jun; 42(6):588-95. PubMed ID: 25809502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six vs Eight Weeks of Antibiotics for Small Mycobacterium ulcerans Lesions in Australian Patients.
    O'Brien DP; Friedman ND; Cowan R; Walton A; Athan E
    Clin Infect Dis; 2020 Apr; 70(9):1993-1997. PubMed ID: 31231766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
    Chauffour A; Robert J; Veziris N; Aubry A; Jarlier V
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005066. PubMed ID: 27755552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
    Sarpong-Duah M; Frimpong M; Beissner M; Saar M; Laing K; Sarpong F; Loglo AD; Abass KM; Frempong M; Sarfo FS; Bretzel G; Wansbrough-Jones M; Phillips RO
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005695. PubMed ID: 28671942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.